SCHEMBL7125059

SCHEMBL7125059

COc1ccc(C(O)C(F)(F)F)cc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 4/20 0.55
TUBB P07437 4/20 0.55
TUBA3C P0DPH7 4/20 0.55
TUBA1B P68363 4/20 0.55
TUBA4A P68366 4/20 0.55
TUBB4B P68371 4/20 0.55
TUBB3 Q13509 4/20 0.55
TUBB2A Q13885 4/20 0.55
TUBB8 Q3ZCM7 4/20 0.55
TUBA3E Q6PEY2 4/20 0.55
TUBA1A Q71U36 4/20 0.55
TUBA1C Q9BQE3 4/20 0.55
TUBB6 Q9BUF5 4/20 0.55
TUBB2B Q9BVA1 4/20 0.55
TUBB1 Q9H4B7 4/20 0.55
CYP19A1 P11511 1/20 0.46
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128355 0.86 TSHR (0.58) CYP19A1NPSR1MEN1KMT2ATSHR
SCHEMBL7120860 0.86 PPARG (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL15561617 0.83 LMNA (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL7127149 0.83 TUBB4A (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL19137397 0.81 TAS1R3 (0.41) MAPTMEN1KMT2ACYP3A4ALDH1A1
SCHEMBL15540035 0.80 ADRA2A (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11562343 0.80 TUBB4A (0.64) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13885076 0.79 TSHR (0.39) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2978450 0.78 TUBB4A (0.62) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL21358371 0.78 TSHR (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030144541-A1 Process for preparing alpha-halogenated retones RHODIA CHIMIE (FR) 2003-07-31 US claimed
EP-1250303-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2002-10-23 EP claimed
WO-2001055067-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2001-08-02 WO claimed
US-20030144541-A1 Process for preparing alpha-halogenated retones RHODIA CHIMIE (FR) 2003-07-31 US disclosed
EP-1250303-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2002-10-23 EP disclosed
WO-2001055067-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144541-A1 Process for preparing alpha-halogenated retones ADH1A, ADH1C, RER1 TUBB4A 2363/4885TUBB 3106/4885TUBA3C 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.